Table 3

Summary of studies on duration of dual antiplatelet therapy (DAPT)

TrialPopulationTime of RxDuration of DAPT (months)Primary outcomeEvent rates (%)HR (95% CI)Interpretation
3691215182124
REAL-LATE/ZEST-LATE (n=2701)DES12 months after PCIMI or CD at 2 years1.81.65 (0.80 to 3.36)DAPT >12 months was not more effective than aspirin monotherapy
1.2
PRODIGY
(n=2013)
DES/
BMS
1 month after PCIDeath, MI, CVA at 2 years10.00.98 (0.74 to 1.29)24 months of DAPT was not more effective than 6 months of DAPT; no significant interaction between the effect of BMS or DES
10.1
EXCELLENT
(n=1443)
DESAt index procedure CD, MI, ischaemia-driven TVR
at 1 year
4.81.14 (0.70 to 1.86)6 months DAPT did not increase TVF at 12 months; ST more common in the 6 months DAPT arm; benefit of 12-month DAPT arm in patients with diabetes
4.3
RESET
(n=2117)
E-ZESAt index procedureCD, MI, ST, TVR, bleeding at 1 year4.7Risk difference 0.0% (95% CI −2.5% to 2.5%)3 months DAPT+E-ZES was non-inferior to 12 months DAPT+DES
DES4.7
OPTIMIZE
(n=3119)
ZESAt index procedureDeath, MI, stroke, major bleeding6.0Risk difference 0.17% (95% CI −1.52% to 1.86%)In patients treated with ZES, 3 months of DAPT was non-inferior to 12 months of DAPT; no significantly increased risk of ST
5.8
  • BMS, bare metal stent; CD, cardiac death; CVA, cerebrovascular accident; DAPT, dual antiplatelet therapy; DES, drug-eluting stent, (E-)ZES, (Endeavor-) Zotarolimus-eluting stent; MI, myocadial infarction; PCI, percutaneous coronary intervention; Rx, randomisation; ST, stent thrombosis; TVF, target vessel failure; TVR, target vessel revascularisation.